Clinical Trial Update: Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the PARP-1 inhibitor BSI-201 in newly diagnosed malignant glioma (glioblastoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BSI-201 (iniparib)

Snippet

Sponsor: Sanofi | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED